spironolactone has been researched along with Ventricular Dysfunction in 5 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Ventricular Dysfunction: A condition in which HEART VENTRICLES exhibit impaired function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 7.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 7.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| " This study's aim was to determine whether chronic spironolactone treatment prevents formation of local electrical activation delays in the cardiomyopathic ventricle by attenuating inflammatory pathways and myocardial fibrosis." | 3.79 | Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation. ( Esposito, CT; Jeyaraj, D; Lu, Y; Stambler, BS; Varahan, S, 2013) |
| "We documented chronic ventricular arrhythmias in a first group of 58 rats after myocardial infarction (MI), then assessed the effects of spironolactone and fosinopril on morphological indexes and arrhythmias in a second group (n = 33)." | 3.71 | Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. ( Beck, L; Blanc-Guillemaud, V; Cherif, OK; Davy, JM; Jover, B, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Esposito, CT | 1 |
| Varahan, S | 1 |
| Jeyaraj, D | 1 |
| Lu, Y | 1 |
| Stambler, BS | 1 |
| Ramírez, E | 1 |
| Klett-Mingo, M | 1 |
| Ares-Carrasco, S | 1 |
| Picatoste, B | 1 |
| Ferrarini, A | 1 |
| Rupérez, FJ | 1 |
| Caro-Vadillo, A | 1 |
| Barbas, C | 1 |
| Egido, J | 1 |
| Tuñón, J | 1 |
| Lorenzo, Ó | 1 |
| Pitt, B | 1 |
| Hernandez, AF | 1 |
| O'Connor, CM | 1 |
| Beck, L | 1 |
| Blanc-Guillemaud, V | 1 |
| Cherif, OK | 1 |
| Jover, B | 1 |
| Davy, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000516] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for spironolactone and Ventricular Dysfunction
| Article | Year |
|---|---|
Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiological Phenomena; Fibrosis; Heart Failure; Heart | 2013 |
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; D | 2013 |
Aldosterone blockade in patients with acute myocardial infarction.
Topics: Acute Disease; Catecholamines; Collagen; Eplerenone; Heart Rate; Humans; Mineralocorticoid Receptor | 2003 |
Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD).
Topics: Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Potassium; Renin-Angiotensin System; Spi | 2003 |
Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Chronic Disease; Disease Mo | 2001 |